技术平台

Platform for Chimeric Antigen Receptor (CAR) T cell therapy

   

Technical Platform for Chimeric Antigen Receptor (CAR) T cell therapy


Chimeric Antigen Receptor T (CAR-T) cell is a genetically engineered T cell. Patient-derived T cells are stably transduced with the gene encoding CAR and are redirected by this receptor to recognize and destroy tumor cells in an HLA-independent manner. The autologous CAR-T cells could be infused back into patients, and mount a potent T cell response against tumor cells that expressing target antigens. 


image.png


Currently, the company possesses a well-established CAR-T cell therapy platform, including yeast surface display-based human single-chain antibody screen library, phage display-based human single-chain antibody screening platform, CAR construct optimization protocol, virus preparation system, CAR-T cell manipulation and functional evaluation platform. 


image.png


 Our research focuses on developing CAR-T cells armed with novel design. Based on the prototype CAR construct, we have constructed several CAR-T derivatives including STAR-T, logic-gated CAR-T, pro-CAR-T, self-driving CAR-T, and dual-targeting CAR-T cells. 


Innovative CAR-T technology platform


image.png